KraneShares MSCI All China Health Care Index ETF(KURE)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$16.81
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for KURE

11/20/2026: KURE (1-star) is currently NOT-A-BUY. Pass it for now.

The KraneShares MSCI All China Health Care Index ETF (KURE) provides targeted exposure to China's expanding medical sector by tracking a market-cap-weighted index of companies listed across Mainland China, Hong Kong, and the US. Its primary strengths lie in its comprehensive share-class access and risk-mitigating 10/40 index capping methodology. It serves as a specialized satellite allocation for investors seeking growth in emerging market healthcare. Key risks involve high sector volatility, localized regulatory policy shifts, and geopolitical tensions. KURE best suits growth-focused investors with a high risk tolerance who wish to monitor demographic and medical reform catalysts in China.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitProvides direct exposure to high-growth biotechnology and pharmaceutical innovators scaling rapidly within a major emerging market.
Momentum investorStrong fit while signal remains positiveCaptures sharp rotational momentum swings when Chinese equity markets experience positive sentiment rallies.
Value investorMixed fitValuations can be volatile and are frequently driven by growth expectations rather than traditional deep-value metrics.
Dividend/Income investorWeak fitThe portfolio focuses primarily on capital appreciation and reinvestment in research-heavy medical firms rather than high dividend payouts.
Low-risk investorWeak fitSubject to substantial emerging market risks, regulatory shifts, and high sector-specific volatility.

Investor Profile

Ideal Investor Profile

Growth-oriented investors looking for tactical, long-term exposure to the structural healthcare transformation and medical modernization taking place in China.

Suitability

Best suited for tactical long-term allocators willing to tolerate higher volatility in exchange for specialized emerging market sector growth.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighThe fund experiences sharp price fluctuations driven by sentiment shifts toward Chinese equities and the biotech sector.
Market riskHighPerformance is closely tied to macroeconomic and geopolitical developments affecting Greater China markets.
ConcentrationMedium / highThough capped, the portfolio concentrates heavily on a select group of top holdings and a single industry sector.
Tracking/expenseLowThe fund exhibits minimal tracking error relative to its benchmark index.
LiquidityMediumUnderlying A-shares and niche listings can occasionally present localized liquidity constraints during market stress.
Business/sector qualityMedium / highConstituents are subject to shifting clinical trial outcomes, regulatory approvals, and healthcare policy reforms.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

KURE displays high historical volatility relative to developed market healthcare funds due to emerging market exposure and single-sector concentration.

Market Risk

Subject to regulatory changes in China, currency fluctuations between the USD and RMB, and shifts in global investor sentiment toward Chinese assets.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
Single stockBeOne Medicines Ltd (06160)9.8Provides top-tier exposure to an innovative global-reaching biopharmaceutical entity shaping oncology therapeutics.
Single stockInnovent Biologics Inc (01801)8.2Offers direct exposure to a premier Chinese biopharma leader specializing in monoclonal antibodies and oncology drugs.
Single stockWuXi Biologics Cayman Inc (02269)7.6Captures growth in global life sciences contract research and biologics drug development manufacturing outsourcing.
Single stockWuXi AppTec Co Ltd (603259)5.6Involves investors in a critical provider of R&D and manufacturing services for the worldwide pharmaceutical industry.
SectorRemaining Chinese Healthcare Equities Basket68.8Diversifies the remainder of the fund across dozens of mid-to-large-cap pharmaceutical, medical device, and healthcare service providers.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type ETF
Historic Profit -8.05%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
ETF Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.